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Purpose: To investigate the natural history of RHO-associated retinitis pigmentosa (RP).
Methods: A multicenter, medical chart review of 100 patients with autosomal dominant
RHO-associated RP.
Results: Based on visual fields, time-to-event analysis revealed median ages of 52 and
79 years to reach low vision (central visual field ,20°) and blindness (central visual field
,10°), respectively. For the best-corrected visual acuity (BCVA), the median age to reach
mild impairment (20/67 # BCVA , 20/40) was 72 years, whereas this could not be
computed for lower acuities. Disease progression was significantly faster in patients with
a generalized RP phenotype (n = 75; 75%) than that in patients with a sector RP pheno-
type (n = 25; 25%), in terms of decline rates of the BCVA (P , 0.001) and V4e retinal
seeing areas (P , 0.005). The foveal thickness of the photoreceptor–retinal pigment
epithelium (PR + RPE) complex correlated significantly with BCVA (Spearman’s r = 0.733;
P , 0.001).
Conclusion: Based on central visual fields, the optimal window of intervention for RHO-
associated RP is before the 5th decade of life. Significant differences in disease progres-
sion are present between generalized and sector RP phenotypes. Our findings suggest that
the PR + RPE complex is a potential surrogate endpoint for the BCVA in future studies.
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Mutations in the RHO gene are associated with theautosomal dominant form of retinitis pigmentosa
(RP).1 Initial symptoms of RP include night blindness
or peripheral visual field (VF) loss, which can be fol-
lowed by the loss of central vision in advanced stages
of the disease. To date, more than 150 mutations in the
RHO gene have been described, which are responsible
for 25% to 30% of all autosomal dominant RP cases.2
RHO mutations have also been described in congenital
stationary night blindness3 and, even more rarely, in
forms of autosomal recessive RP.4 Another phenotype
commonly described in RHO mutations is sector RP,
which is characterized by regional photoreceptor
degeneration, typically confined to the inferior quad-
rant of the retina.5,6 Sector RP is considered a station-
ary to slowly progressive disease but may eventually
lead to a more severe, diffuse RP phenotype.7
The RHO gene encodes the protein rhodopsin,
located in the outer segment of rod photoreceptor cells,
containing extracellular, transmembrane, and cytoplas-
mic domains.1 Previous studies have shown that the
clinical expression of RHO-associated RP correlates
with the protein domain affected by the mutation.8
Mutations affecting the cytoplasmic domain of rho-
dopsin are more likely to cause a severe RP pheno-
type, with early loss of rod and cone function. By
1
contrast, patients with mutations affecting the extracel-
lular domain generally have a milder phenotype, with
relatively preserved rod and cone function and slower
disease progression.9,10
No curative treatment for RHO-associated RP is
currently available, but promising results have been
achieved by knockdown and replacement gene therapy
in animal models.11,12 To guide the design of upcom-
ing clinical trials, more insights into the natural disease
progression in RHO-associated RP are necessary. A
more detailed clinical disease profile will aid in the
selection of eligible candidates and in the establish-
ment of appropriate clinical endpoints for future trials.
The purpose of this longitudinal study was to provide
a description of the clinical variability and the natural




Data of patients with RHO-associated RP were col-
lected from the patient database for hereditary eye dis-
eases (Delleman Archive) at the Amsterdam University
Medical Center (the Netherlands) from various other
Dutch tertiary referral centers within the RD5000 con-
sortium13 and from the Ghent University Hospital in
Belgium. Inclusion criteria were as follows: a molecular
confirmation of a (likely) pathogenic variant in the RHO
gene or a first-degree relative with similar clinical find-
ings and a molecular confirmation of a RHO mutation.
In total, 100 patients with RHO-associated RP were
included for analysis in this study. Approval from the
ethics committee was obtained before the study as well
as the local institutional review board approval in all
participating centers. Dutch participants provided
informed consent for the use of their patient data for
research purposes. For Belgian participants, the local
ethics committee waived the need for informed consent
on the condition of pseudonymization.
Data Collection
A standardized review of medical records was
performed for data on the initial symptoms, best-
corrected visual acuity (BCVA), findings on slit-lamp
examination and fundoscopy, Goldmann VFs, full-
field electroretinogram (ERG), spectral-domain optical
coherence tomography (SD-OCT), and fundus auto-
fluorescence (FAF) imaging, where available. Gold-
mann VFs were digitized and converted to retinal
seeing areas using methods previously described by
Dagnelie.14
In patients with available OCT and FAF imaging in
Heidelberg (Heidelberg Engineering, Heidelberg,
Germany), automatic and manual measurements of
retinal layers were performed using the inbuilt
software of Heidelberg. The thickness of the
photoreceptor–retinal pigment epithelium complex
(PR + RPE) was defined as the foveal distance
between the external limiting membrane and the basal
border of the RPE, as described previously (see
Figure, Supplemental Digital Content 1, http://
links.lww.com/IAE/B219).15 All measurements were
performed by two authors (X.-T.-A.N. and M.T.) and
reviewed by C.J.F. Boon in case of inconsistency
between the aforementioned two authors.
Statistical Analysis
Data were analyzed using SPSS version 23.0 (IBM
Corp, Armonk, NY) and the R software environment.16
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Findings with a P value of , 0.05 were considered
statistically significant. Normally and nonnormally dis-
tributed data were displayed as means with SDs and
medians with interquartile ranges (IQRs), respectively.
To measure the time to visual impairment, a time-to-
event analysis was performed using the nonparametric
maximum likelihood estimator method to account for
left-censored, interval-censored, and right-censored
data. Visual impairment endpoints were based on the
criteria of the World Health Organization: no visual
impairment (BCVA $ 20/40), mild visual impairment
(20/67 # BCVA , 20/40), low vision (20/200 #
BCVA , 20/67), severe visual impairment (20/400
# BCVA , 20/200), or blindness (BCVA , 20/
400). For VFs, the following endpoints were used: mild
impairment (20°# central VF, 70°), low vision (cen-
tral VF , 20°), and blindness (central VF , 10°).
Because of the presence of repeated measurements,
a linear mixed model analysis was performed to mea-
sure disease progression. For hand movement vision,
light perception vision, and no light perception, loga-
rithm of the minimum angle of resolution (logMAR)
values of 2.7, 2.8, and 2.9 were used, respectively.17
Structure–function correlations were analyzed using
Spearman correlation coefficients. To analyze
genotype–phenotype associations, patients were strati-
fied into the following three groups based on the
affected protein domain: cytoplasmic, transmembrane,
or extracellular.
Results
Clinical and Genetic Characteristics
One hundred patients from 47 families, with
autosomal dominant RHO mutations, were included
from the Dutch (n = 63; 63%) and Belgian (n = 37;
37%) population. No differences in baseline character-
istics between these two populations were present (see
Table, Supplemental Digital Content S2, http://
links.lww.com/IAE/B220). Patients with available lon-
gitudinal data (n = 72; 72%) had a median follow-up
time of 6.9 years (IQR 11.9; range: 0.2–41.0) and
a median of 5.0 visits (IQR 6.0; range: 2.0–31.0).
Seventy-five patients (75%) had a generalized form
of RP on fundus examination (Figure 1), whereas 25
patients (25%) showed a sector RP phenotype, with
pigmentary changes confined to the inferior hemi-
sphere in all cases. The clinical characteristics of the
entire cohort are summarized in Table 1.
In total, 23 different missense mutations, 1 in-frame
deletion, and 1 novel splice-site mutation were found
in the RHO gene (see Table, Supplemental Digital
Content S3, http://links.lww.com/IAE/B221). Patients
were stratified, based on the affected protein domain,
as carrying extracellular (n = 64; 64%), transmem-
brane (n = 20; 20%), or cytoplasmic (n = 15; 16%)
mutations, excluding the splice-site mutation. We
found a high proportion of extracellular mutations
(24/25; 96%) in the sector RP group. The most com-
mon pathogenic variant in this study, p.(Glu181Lys),
was found in four families, comprising 23 of the 63
Dutch patients (37%). This mutation was not found in
the Belgian cohort. Common mutations exclusively
found in the Belgian cohort were p.(Ile255del) (n =
6) and p.(Tyr178Asp) (n = 6), each belonging to a sin-
gle family, accounting for 12 of the 37 Belgian pa-
tients (32%).
Visual Function
Best-corrected visual acuity data were available for
95 patients, with a high degree of symmetry between
eyes (Spearman’s r = 0.888; P , 0.001). In 25 pa-
tients, a degree of BCVA-based visual impairment was
present during the last examination (see Figure, Sup-
plemental Digital Content 4, http://links.lww.com/
IAE/B222). Time-to-event analysis of the entire cohort
revealed a median age of 72 years to reach mild visual
impairment, whereas the median ages for low vision,
severe visual impairment, and blindness could not be
computed (Figure 2). First occurrences of low vision
were seen from the 3rd decade of life onward, whereas
severe visual impairment and blindness were seen
from the 5th decade of life onward. In the sector RP
cohort, the first occurrence of blindness was seen after
the 8th decade of life in a patient with age-related
macular degeneration. Linear mixed model analysis
revealed an age effect on the mean BCVA, which
was 0.012 logMAR (22.9%; P , 0.001) per year
for the entire cohort. The BCVA decline was signifi-
cantly faster in patients with a generalized RP pheno-
type than that in patients with a sector RP phenotype
(P = 0.002), with BCVA progression rates of 0.012
logMAR (23.8%; P , 0.001) and 20.002 logMAR
(+0.4%; P = 0.671) per year, respectively. For patients
with generalized RP, we found no differences in base-
line BCVA values (P = 0.360) or in progression slopes
(P = 0.168) between affected protein domains.
Initial ERG findings were documented in 52 patients
(Table 1). Minimal and nondetectable ERG responses
were only found in the generalized RP group. The
mean age at which nondetectable ERG responses were
first observed was 35.3 years (SD 16.1; range 17.1–
63.7). Longitudinal ERG data were available for 10
patients, with a mean follow-up time of 6.7 years
(SD 4.0; range 0.5–13.6). Eight patients showed no
clear changes in ERG patterns during follow-up.
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Two patients, aged 29 and 26 years, displayed rod–
cone patterns at the initial visit, which progressed to
minimal and absent responses over a time span of 8.6
and 13.6 years, respectively.
Original Goldmann VF records were available for 59
patients, with a high degree of symmetry between eyes
for the V4e (Spearman’s r = 0.957; P , 0.001) and the
I4e (Spearman’s r = 0.935; P , 0.001) retinal seeing
areas. Various patterns of VF defects were observed,
ranging from mild concentric constriction to central
islands (Figure 3). Intrafamilial variability was present,
as patients carrying the p.(Glu181Lys) mutation could
demonstrate different VF defects (Figure 3, A and B).
Time-to-event analysis of the VFs revealed median ages
of 44, 52, and 79 years for mild visual impairment, low
vision, and blindness, respectively (Figure 1B). For the
Fig. 1. Color fundus photogra-
phy in this cohort of RHO-
associated RP. A–C. Illus-
trations of interfamilial and in-
trafamilial variability fundus in
a family with p.(Tyr178Asn)
mutations in the RHO gene. A.
Patient-ID 65, aged 38 years,
with mutation p.(Tyr178Asn).
Peripapillary atrophy and mod-
erate peripheral chorioretinal
atrophy was present on fundus
photography. No intraretinal
hyperpigmentation was seen
(BCVA: 20/20 in both eyes). B.
Patient-ID 66, aged 45 years,




tation in the midperiphery
(BCVA right eye: 20/25; BCVA
left eye: 20/67). C. Patient-ID
63, aged 50 years, carrying
a p.(Tyr178Asn) in RHO. Fun-
dus photography revealed
optic disk pallor, attenuated
vessels, ring-shaped atrophy in
the macula, and diffuse intra-
retinal bone-spicule hyper-
pigmentations (BCVA was
20/400 in both eyes). D. Patient-
ID 52, aged 45 years, with RHO
mutation p.(Glu28His). A sec-
torial RP phenotype is seen on
color fundus photography of the
right eye, with peripapillary
atrophy and atrophic areas and
bone-spicule hyperpigmentation
around the inferior vascular
arcade (BCVA: 20/20 in both
eyes). E. Patient-ID 51, aged 87
years, with RHO mutation
p.(Leu40Pro). Fundus photogra-
phy showed mild optic disk
pallor with retinal atrophy fol-
lowing the superior and inferior
vascular arcade. Geographic
atrophy is visible at the macula
of the left eye, resulting in
a BCVA of only light percep-
tion. F. Patient-ID 80, aged 74
years, carrying a p.(Asn15Ser)
mutation in RHO. Fundus pho-
tography of the left eye revealed
paravascular atrophy mainly in the inferior quadrant with the pigment clumping around these atrophic areas. Drusen can be seen around the macula
(BCVA right eye: 20/22; BCVA left eye: 20/67). G. Patient-ID 48, aged 74 years, with the p.(Asp190Gly) RHO mutation, showing advanced RP. A
pale fundus with a waxy pale optic disk, severely attenuated vessels, CME, and bone-spicule hyperpigmentation in the midperipheral retina (BCVA
right eye: 20/667; BCVA left eye: 20/1,000).
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V4e retinal seeing areas, a faster decline of retinal see-
ing areas was observed in patients with generalized RP
than in patients with sector RP (P = 0.005), with a sig-
nificant decline rate of 25.6% per year (P , 0.001) for
patients with generalized RP, but not in patients with
sector RP (+1.7% per year, P = 0.477). No differences
in V4e retinal seeing areas were seen between domains
at baseline (P = 0.240) nor with increasing age (P =
0.085) in patients with generalized RP. For the I4e
retinal seeing areas, we found the age effect to be





RP (n = 75)
Sector
RP (n = 25) P
Male (%) 44 (44) 34 (46) 10 (39) 0.642
Age at the last examination (n = 100)
Mean ± SD 43.5 ± 18.5 42.5 ± 19.3 45.5 ± 22.6 0.204
Initial symptoms (n = 55)
Nyctalopia, n (%) 41 (75) 28 (74) 2 (40)
VF loss, n (%) 5 (9) 3 (8) 1 (20)
Visual acuity loss, n (%) 3 (5) 2 (5) 1 (20)
Multiple symptoms, n (%) 6 (11) 5 (13) 1 (20) 0.890*
Age at onset in years (n = 55)
Early childhood, n (%) 21 (38) 16 (29) 5 (9)
Median age (IQR) 13.5 (12.5) 11.0 (11.8) 15.7 (12.5) 0.829
Mean refractive error, in D (n = 66)
Mean ± SD 0.8 ± 2.85 1.0 ± 3.27 0.2 ± 1.4 0.298
BCVA in the better-seeing eye (n = 95)
Median BCVA, in Snellen (IQR) 20/25 (20/30) 20/30 (20/30) 20/20 (20/200) ,0.001
BCVA in the worst-seeing eye (n = 95)
Median BCVA, in Snellen (IQR) 20/30 (20/25) 20/33 (20/30) 20/22 (20/60) 0.002
ERG patterns (n = 52)
Normal responses, n (%) 2 (4) — 2 (11)
Reduced responses, n (%)† 5 (10) 1 (3) 4 (22)
Rod–cone patterns, n (%) 28 (54) 16 (47) 12 (67)
Minimal responses, n (%) 6 (11) 6 (18) —
Nondetectable, n (%) 11 (21) 11 (32) — ,0.001*
Retinal seeing areas, V4e (n = 57)‡
Median seeing areas, in mm2 (IQR) 256.4 (545.6) 128.0 (552.4) 487.2 (248.3) 0.067
Retinal seeing areas, I4e (n = 55)‡
Median seeing areas, in mm2 (IQR) 17.4 (101.4) 14.5 (66.5) 130.6 (194.36) 0.011
VF patterns (n = 75)
Normal, n (%) 1 (1) 1 (2) —
Peripheral constriction, n (%) 24 (32) 19 (32) 5 (31)
Midperipheral scotoma, n (%) 6 (8) 5 (9) 1 (6)
Central island with peripheral
remnants, n (%)
18 (24) 15 (25) 3 (19)
Central preservation, n (%) 19 (25) 18 (30) 1 (6)
Superior hemisphere, n (%) 7 (10) 1 (2) 6 (38) 0.002*
CME, n (%) 16/32 (50) 14/25 (56) 2/7 (29) 0.225*
Central retinal thickness (n = 32)‡
Median thickness in mm (IQR) 253.0 (94.0) 254.0 (122.0) 248.5 (92.5) 0.858
Outer nuclear layer thickness (n = 32)‡
Median thickness in mm (IQR) 97.5 (47.25) 89.5 (52.5) 110.5 (41.9) 0.121
PR + RPE thickness (n = 32)‡
Median thickness in mm (IQR) 90.5 (18.3) 89.5 (20.0) 95.3 (18.1) 0.147
EZ bandwidth (n = 26)‡
Mean width in mm ± SD 2,704.5 ± 1881.9 2,125.0 ± 1,544.8 4,277.5 ± 1909.6 0.007
Hyper-AF ring diameter (n = 15)‡
Horizontal border in mm ± SD 3,541.6 ± 1930.6 3,484.9 ± 2058.5 3,910.3 ± 1,009.4 0.571
Vertical border in mm ± SD 2,652.7 ± 1,567.7 2,594.9 ± 1,628.0 3,201.5 ± 883.2 0.286
Significant P values (P , 0.05) are indicated in bold. The last available examination was used for documentation.
*Fisher’s exact test was performed.
†No clear rod or cone response was documented.
‡Averaged between eyes.
D, diopters.
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Fig. 2. Time-to-event analysis
illustrating the time to reach
visual impairment based on the
definition set by the World
Health Organization. Because of
the presence of left-censored,
interval-censored, and right-
censored data to estimate the
time to reach low vision, severe
impairment, and blindness, the
nonparametric maximum likeli-
hood estimator was used. A.
Time-to-event analysis of the
BCVA in the better-seeing eye
demonstrating the time to reach
mild visual impairment [(20/67
# BCVA , 20/40), low vision
(20/200 # BCVA , 20/67),
severe visual impairment (20/
400 # BCVA , 20/200), or
blindness (BCVA , 20/400). B.
For central VFs, the following
endpoints were used: mild
impairment (20°# central VF,
70°), low vision (central VF ,
20°), and blindness (central VF
, 10°).
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25.5% per year (P , 0.001) in patients with general-
ized RP and +0.2% per year (P = 0.930) in patients with
sector RP. For patients with generalized RP, we found
differences at baseline (P = 0.013), with larger I4e ret-
inal seeing areas in patients with extracellular mutations
than those in patients with transmembrane (P = 0.005)
or cytoplasmic (P = 0.026) mutations. No differences in
progression slopes of I4e retinal seeing areas were
observed between affected domains (P = 0.233).
Multimodal Imaging
Spectral-domain OCT imaging was performed in 32
patients, with thickness measurements of retinal layers
specified in Table 1. We found cystoid macular edema
(CME) in 16 of the 32 patients (50%), which was
located in the fovea for 12 of the 16 (75%) patients.
No significant age effect was found on central retinal
thickness (P = 0.371) or outer nuclear layer thickness
(P = 0.502), after exclusion of patients with foveal
CME. For PR + RPE measurements, advancing age
was associated with the loss of PR + RPE thickness
(20.6% per yr; P = 0.030), which was not affected by
a sector RP phenotype (P = 0.611). The PR + RPE
thickness was the only parameter, after exclusion of
patients with foveal CME and correction for multiple
testing, that correlated with the BCVA (Table 2). The
macular ellipsoid zone (EZ) bandwidth, measurable in
Fig. 3. Representative patterns
of VF loss in patients with RHO-
associated RP. A and B. Intra-
familial variability in a family
carrying the p.(Glu181Lys)
mutation. A. Patient-ID 30, aged
54 years, showed a central island
with peripheral remnants
(BCVA right eye: 20/100;
BCVA left eye: 20/125) on
kinetic perimetry, whereas the
younger brother (B), aged 46
years, had an absolute scotoma
in the superior hemifield
(BCVA: 20/16 in both eyes). C.
Patient-ID 52, aged 43 years,
with the RHO missense mutation
p.(Glu28His). An incomplete
midperipheral annular scotoma
was visible in the left eye
(BCVA right eye: 20/25;
BCVA left eye: 20/20). D.
Patient-ID 39, aged 52 years,
with a c.937-2A.C [p.(?)]
splice-site mutation in RHO,
showing a complete ring sco-
toma in the right eye (BCVA
right eye: 20/67; BCVA left
eye: 20/400). E. Patient-ID 59,
aged 22 years, with RHO
mutation p.(Arg135Trp), show-
ing severe constriction of the
V4e and I4e isopters with cen-
tral preservation of the VF and
small midperipheral VF rem-
nants (BCVA right eye: 20/67;
BCVA left eye: 20/40). F.
Patient-ID 44 (38 years of age),
carrying the p.(Asp190Tyr)
RHO mutation, had marked
peripheral VF loss with only
a residual central island re-
maining (BCVA right eye: 20/
50; BCVA left eye: 20/32).
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26 of the 32 (81%) patients, decreased with advancing
age (23.8%; P , 0.001), which was not significantly
different in patients with sector RP (P = 0.589). How-
ever, a larger EZ bandwidth at baseline was seen in
patients with a sector RP phenotype (P = 0.018). For
patients with generalized RP, no differences in the EZ
bandwidth at baseline (P = 0.185) or for the decline
rates (P = 0.886) were observed between affected pro-
tein domains. In 6 of the 26 patients (23%), the EZ
bandwidth went beyond the scanning range on SD-
OCT (Figure 4A). A granular interrupted aspect of
the EZ bandwidth was seen in 9 of the 26 (35%)
patients.
Fundus AF imaging, available for 38 patients,
revealed hyperautofluorescent (hyper-AF) and hypo-
autofluorescent (hypo-AF) patterns in variable de-
grees, including a hyper-AF macular ring in 26 of
the 38 (68%) patients (Figure 4). In patients with sec-
tor RP, a common pattern seen on FAF was a hypo-AF
distribution along the inferior vascular arcade, which
corresponded with areas of degeneration seen on fun-
dus photography (Figure 4D). A high degree of corre-
lation was found between EZ bandwidth and the
horizontal (r = 0.923; P , 0.001) and vertical borders
(r = 0.937; P , 0.001) of the hyper-AF macular ring.
Discussion
This multicenter study provides a detailed description
of the natural history of RHO-associated autosomal
dominant RP, using cross-sectional and longitudinal
data. We found a high prevalence of the p.(Gly181Lys)
mutation (n = 23) in four different families, accounting
for 37% of the Dutch cohort. This mutation has rarely
been described in other populations, which is sugges-
tive of a founder effect of p.(Gly181Lys) in the Dutch
RHO-associated autosomal dominant patients. Com-
mon mutations exclusively found in the Belgian pa-
tients of our cohort were p.(Ile255del) and
p.(Tyr178Asp). The p.(Tyr178Asp) mutation has never
been described outside the Belgian population,18
whereas the p.(Ile255del) mutation has previously been
found in a single Irish family.19
Several mutations, such as p.(Glu181Lys), found in
this cohort could present as either generalized or sector
RP, which underlines the potential influence of genetic
and/or other modifiers on the phenotype. As suggested
previously, it is possible that sector RP will eventually
transition into a generalized RP phenotype in later
stages of the disease.7 However, we were not able to
observe this transition in any of our patients. In addi-
tion, we found patients who retained a sector RP phe-
notype up to the 8th decade of life.
Our reported progression rates of the BCVA
(23.8% per yr) and V4e retinal seeing areas
(25.6% per yr) in patients with generalized RP were
faster than those reported by a previous natural his-
tory study on RHO-associated RP, which reported
rates of 21.8% per year for the BCVA and 22.6%
per year for V4e retinal seeing areas.9 One possible
explanation for this discrepancy is the difference in
statistical methods. In contrast to the study of Berson
et al,9 we analyzed patients with sector RP separately
because these patients demonstrated minimal disease
progression and may contribute to a ceiling effect. In
addition, there are notable genetic differences
between our population and the one in the American
study by Berson et al. The p.(Pro23His) mutation,
which is the most common RHO mutation in the
United States (36% in their cohort), is known to
express a particularly mild phenotype and is also
described in patients with sector RP.20 To the best
of our knowledge, this founder mutation has never
been reported in European studies, including the pres-
ent one.21,22
Table 2. Structure and Function Correlations in RHO-Associated RP
Visual Function Parameter
BCVA (logMAR) Seeing Retinal Area V4e Seeing Retinal Area I4e
Spearman’s rho P Spearman’s rho P Spearman’s rho P
SD-OCT imaging
CRT* 20.370 0.095 0.291 0.274 0.086 0.770
ONL thickness* 20.234 0.366 20.029 0.923 20.162 0.596
PR + RPE thickness* 20.733 ,0.001 0.528 0.053 0.556 0.049
EZ bandwidth 20.506 0.054 0.198 0.517 0.280 0.379
FAF imaging
Horizontal ring diameter 20.339 0.235 0.632 0.024 0.643 0.021
Vertical ring diameter 20.245 0.419 0.615 0.037 0.566 0.059
The most recent mean values between right and left eyes were used for analysis. Imaging and measurements were performed using the
Heidelberg inbuilt software (Spectralis SD-OCT + HRA, Heidelberg Engineering, Heidelberg, Germany). The significance level was set at
0.003 after Bonferroni correction. Significant values are in bold.
*Patients with CME located in the fovea were excluded from analysis.
CRT, central retinal thickness; ONL, outer nuclear layer.
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Patients with a generalized form of RP were
stratified based on the domains affected by RHO mu-
tations. At baseline, we found larger EZ bandwidths
on OCT and I4e retinal seeing areas on Goldmann VF
in patients carrying extracellular mutations than in pa-
tients with transmembrane or cytoplasmic mutations.
No differences in annual decline rates of EZ band-
widths and I4e retinal seeing areas were found
between mutated protein domains. In addition, muta-
tions causing sector RP, showing minimal disease pro-
gression, were predominantly found in the
extracellular domains. These findings support previous
research in suggesting that extracellular mutations
cause milder phenotypes in RHO-associated RP.23–25
The differences in disease expression between affected
domains can be attributed to the biochemical defects
caused by the mutations within these domains,
although external modifiers such as increased light
exposure, especially in the development of sector
RP, may also play a role.2,7
A limitation of this study is its retrospective nature,
which limited a complete ascertainment of clinical
data. Electroretinogram data were not available for all
patients and were mainly performed at baseline for
Fig. 4. Fundus AF and corre-
sponding SD-OCT imaging in
patients with RHO-associated
RP. A. Patient-ID 81, aged 47
years, carrying the missense
mutation p.(Asn15Ser). Fundus
AF imaging showed an inferior
sectoral hypo-AF and ERG re-
sponses were reduced in a rod–
cone pattern. Spectral-domain
OCT imaging in this patient re-
vealed central preservation of
outer retinal layers but with
thinning of these layers in the
peripheral macula. The EZ
bandwidth went beyond the
scanning range nasally (BCVA
right eye: 20/20; BCVA left eye:
20/22). B. Patient-ID 70, aged
26 years, with a p.(Glu181Lys)
missense mutation. A well-
demarcated hyper-AF ring was
visible on FAF, with hypo-AF
regions inside the hyper-AF
ring. A small hyper-AF spot was
seen at the foveal site, corre-
sponding to the site of CME on
SD-OCT. The midperipheral
retina displayed normal AF re-
gions surrounded by granular
hypo-AF in variable intensities.
Cystoid fluid collections were
present in the inner and outer
nuclear layer (BCVA right eye:
20/28; BCVA left eye: 20/33).
C. Patient-ID 88, aged 60 years,
carrying a p.(Pro347Leu) mis-
sense mutation in the RHO gene.
Fundus AF imaging reveals the
near absence of AF in the fovea
and midperipheral retina, with
residual AF remaining in the
posterior pole. No evident
hyper-AF ring is seen. Profound
atrophy of all retinal layers is
present on SD-OCT, with
increased visibility of the
underlying choroidal vessels. Granular remnants of the EZ are seen at the central fovea, but the EZ is completely absent in the peripheral macula
(BCVA was 20/400 in both eyes). D. Patient-ID 80, aged 74 years, carrying the RHO missense mutation p.(Asn15Ser). Fundus AF imaging showed
sectorial degeneration hypo-AF along the inferior vascular arcade, corresponding with the RPE atrophy seen on fundus photography (Fig. 1F). On SD-
OCT, a pigment epithelial detachment was observed. The partly hyperreflective structures underlying the RPE detachment suggest the presence of
a neovascular membrane. The different layers of the neuroretina were still discernible, with a BCVA of 20/33 and 20/22 in the right and left eye,
respectively.
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diagnostic purposes. For this reason, a previously used
classification system could not be applied to this
cohort.10,23,24 A prospective standardized natural his-
tory study on RHO-associated RP, which is currently
unavailable to the best of our knowledge, should be
able to address such limitations.
Preclinical studies on several gene knockdown and
replacement strategies for RHO-associated RP have
shown promising results, paving the way for human
gene therapy trials.11,12 Our current clinical findings
can have significant implications for future clinical
treatment trials. We found a high degree of between-
eye symmetry for all visual parameters (BCVA, V4e,
and I4e seeing retinal areas), supporting the use of the
fellow eye as a control in intervention studies. On SD-
OCT imaging, we found a high prevalence of CME,
which may be a concern for future gene therapy trials
because the presence of CME may alter the retinal
morphology, challenging correct injection of viral vec-
tors into the subretinal space and posing additional
risks for preoperative and postoperative complica-
tions.26 The borders of the hyper-AF ring on FAF
imaging, which demarcates the transition zone
between the affected and unaffected retina,27 corre-
lated strongly with the EZ bandwidth. Fundus AF
imaging should be used in conjunction with SD-
OCT to capture disease progression in less advanced
stages of RHO-associated RP, in which the EZ band-
width can go beyond the 30° scanning range of SD-
OCT (occurring in 23% of our cases).
The optimal intervention window for RHO-associ-
ated RP is before the 5th decade of life because time-
to-event analysis of VFs revealed median ages of 52
and 79 years for low vision and blindness, respec-
tively. The use of the visual acuity as an endpoint
may be impractical for RHO-associated RP because
of the relatively late onset of BCVA-based impair-
ment. Therefore, the use of surrogate endpoints for
the visual acuity could accelerate the measurement
of disease progression and treatment response. We
and others have previously found that the PR + RPE
complex has been suggested to be a good predictor of
the visual acuity.15,28–30 Similar results were found in
this study because the PR + RPE complex correlated
strongly with the BCVA, and it was the only param-
eter that remained significant after correction for mul-
tiple testing. The PR + RPE complex can potentially
be used to identify early structural changes before the
visual acuity loss may be noticeable, which can be
particularly useful in diseases with relatively slow dis-
ease progression such as RHO-associated RP. In antic-
ipation of future clinical trials for RHO, the
establishment of potential clinical endpoints is a neces-
sary step for an optimal study design. In this regard,
this study highlights the potential use of the PR + RPE
complex as a surrogate endpoint for the BCVA in
future clinical trials.
Key words: inherited retinal dystrophies, natural
history, retinitis pigmentosa, rhodopsin, sector retinitis
pigmentosa.
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